Private equity firms have moved aggressively into the healthcare industry’s more hidden niches: They are pouring billions into the business of clinical drug trials.
After finding success investing in the more obviously lucrative corners of American medicine like surgery centers and dermatology practices private equity firms have moved aggressively into the industry’s more hidden niches: They are pouring billions into the business of clinical drug trials. To bring a new drug to market, the FDA requires pharmaceutical
After finding success investing in the more obviously lucrative corners of American medicine like surgery centers and dermatology practices private equity firms have moved aggressively into the industry's more hidden niches: They are pouring billions into the business of clinical drug trials.